Evidence map›Paper›PMID 27495180›Full record

ArticlePharmaceutical research2016

Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.

Chawan Manaspon, Norased Nasongkla, Khuanjit Chaimongkolnukul, Pinunta Nittayacharn, Ketpat Vejjasilpa, Kanchana Kengkoom, Atthaporn Boongird, Suradej Hongeng

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Frontiers in bioengineering and biotechnology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Injectable biomaterials for treatment of glioblastoma.Advanced materials interfaces · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chawan ManasponDepartment of Biomedical Engineering, Faculty of Engineering, Mahidol University, 25/25 Puttamonthon 4th Rd., Nakorn Pathom, 73170, Thailand.
Norased NasongklaDepartment of Biomedical Engineering, Faculty of Engineering, Mahidol University, 25/25 Puttamonthon 4th Rd., Nakorn Pathom, 73170, Thailand. norased.nas@mahidol.ac.th.
Khuanjit ChaimongkolnukulAcademic Services Office, National Laboratory Animal Center, Mahidol University, Nakhorn Pathom, 73170, Thailand.
Pinunta NittayacharnDepartment of Biomedical Engineering, Faculty of Engineering, Mahidol University, 25/25 Puttamonthon 4th Rd., Nakorn Pathom, 73170, Thailand.
Ketpat VejjasilpaDepartment of Biomedical Engineering, Faculty of Engineering, Mahidol University, 25/25 Puttamonthon 4th Rd., Nakorn Pathom, 73170, Thailand.
Kanchana KengkoomAcademic Services Office, National Laboratory Animal Center, Mahidol University, Nakhorn Pathom, 73170, Thailand.
Atthaporn BoongirdDepartment of Surgery, Neurosurgical Unit, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
Suradej HongengDepartment of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
Mahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSN-38, a potent chemotherapeutic drug, has not been used clinically because of its severe side effects and poor solubility. In this work, we aimed to evaluate the effect of dose and multiple injections of SN-38-loaded polymeric depots on antitumor efficacy and toxicity in vivo.

methodsPreparation and characterization of SN-38-loaded depots were performed and evaluated in vitro using human glioblastoma cell line, U-87MG. Antitumor efficacy with different depot administrations including dose, position of depot injection and number of injections were evaluated in tumor model in nude mice.

resultsDepots encapsulated SN-38 with high encapsulation efficiency (~98.3%). High amount of SN-38 (3.0 ± 0.1 mg) was prolonged and controlled release over time and showed anticancer activity against U-87MG cell line in vitro. For one course administration, depots exhibited better antitumor efficacy and reduced toxicity compared to free SN-38. Elevated doses and multiple injections of SN-38-loaded depots and free SN-38 provided greater tumor growth inhibition and animal survival. All animals received SN-38-loaded depots were well tolerated and survived while most of those received free SN-38 died at day 30. Free SN-38 showed severe toxic effect compared to minimal toxicity from SN-38-loaded depots which was due to lower SN-38 level in systemic circulation. Fluorescence imaging and histopathology confirmed that SN-38 released from depots was detected throughout tumors 35 days post administration.

conclusionsSN-38-loaded depots were proved as a promising new treatment for highly invasive glioblastoma multiforme with low acute toxicity due to controlled release of SN-38.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicBrain NeoplasmsCamptothecinCell Culture TechniquesCell Line, TumorChromatography, High Pressure LiquidDrug Delivery SystemsDrug LiberationFemaleGlioblastomaHeterograftsHumansInjectionsIrinotecanMice, Inbred BALB CAntineoplastic Agents, PhytogenicCamptothecinIrinotecanPolyesterspoly(ethylene glycol)-b-poly(lactide-co-epsilon-caprolactone)Polyethylene Glycolsbiodegradable polymersdrug delivery systemglioblastoma multiformeintratumoral injectionSN-38

Identifiers

PMID27495180
OpenAlexW2476457609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.